Desmoplastic Small Round Cell Tumor (DSRCT) is an aggressive malignancy that clinicians typically encounter in male adolescents and young adults. However, this condition is exceptionally rare in the ovary, making its identification a significant clinical challenge. Recent research suggests that an Ovarian DSRCT subclassification may provide vital prognostic information. By distinguishing between specific anatomical presentations, oncologists can better predict patient outcomes and tailor multimodal therapies.

Case Presentation and Morphologic Complexity

A 33-year-old woman recently presented with a pelvic mass and widespread peritoneal metastases. Histopathological examination revealed the characteristic small round cell nests embedded within a dense desmoplastic stroma. Additionally, the tumor exhibited atypical architectural patterns, including single-file, follicular-like cystic, and microcystic arrangements. Notably, immunohistochemistry demonstrated the coexpression of epithelial markers like pan-keratin and mesenchymal markers such as desmin and vimentin. Molecular analysis ultimately confirmed the pathognomonic EWSR1-WT1 gene fusion, securing the diagnosis.

The Prognostic Impact of Ovarian DSRCT Subclassification

To better understand survival variations, researchers conducted a comprehensive review of 23 ovarian DSRCT cases. Consequently, they proposed a new Ovarian DSRCT subclassification consisting of two main categories: ovarian-dominant and extraovarian-dominant subtypes. Ovarian-dominant patients demonstrated a significantly prolonged median survival of 24 months. In contrast, those with the extraovarian-dominant subtype faced a median survival of only 10 months. This statistical difference underscores the importance of primary tumor location in determining the clinical trajectory of this rare disease.

Clinical Challenges and Diagnostic Mimicry

Ovarian DSRCT remains a diagnostic pitfall because it mimics many common gynecological and mesenchymal malignancies. Furthermore, the atypical morphological features observed in recent cases can lead to potential misclassification. While multimodal therapy involving surgery and chemotherapy remains the standard approach, outcomes often remain poor. Therefore, clinicians must utilize molecular testing to confirm the EWSR1-WT1 fusion in any suspicious small round cell tumor of the ovary.

Frequently Asked Questions

What is the primary genetic driver of ovarian DSRCT?

The definitive genetic marker for DSRCT is the EWSR1-WT1 gene fusion, which results from a reciprocal translocation between chromosomes 11 and 22. This fusion is essential for confirming the diagnosis in cases with atypical morphology.

How does the ovarian DSRCT subclassification affect prognosis?

Patients classified as having the ovarian-dominant subtype typically experience a longer survival period (median 24 months) compared to those with the extraovarian-dominant subtype (median 10 months). This classification helps clinicians communicate more accurate expectations to patients.

What are the common immunohistochemical markers for DSRCT?

DSRCT is characterized by a multi-phenotypic expression profile. This typically includes the coexpression of pan-keratin (epithelial), desmin (muscle), vimentin (mesenchymal), and neuron-specific enolase (neural) markers.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Shi F et al. Desmoplastic Small Round Cell Tumor of the Ovary: A Case Report With Atypical Morphologic Features and Literature Review. Int J Surg Pathol. 2026 Mar 13. doi: 10.1177/10668969251412899. PMID: 41823035.

Saadi H et al. Ovarian desmoplastic small round cell tumors: Prognosis is poor! Case report. Open Journal of Obstetrics and Gynecology. 2013;3:235-238.

Lee SH et al. Desmoplastic Small Round Cell Tumor with Ovarian Involvement. J Pathol Transl Med. 2009;43(2):185-189.